HIF1A and breast carcinoma: To know the RNA stability of circHIF1A and HIF-1α mRNA, the cells were treated with Actinomycin D at the indicated time points in breast cancer cells and the data showed that the half survival time of circHIF1A was not influenced (Fig. 2F).